Apr 24 |
Biogen Beats Estimates as Alzheimer’s Drug Gains Traction
|
Apr 24 |
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
|
Apr 24 |
Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts
|
Apr 24 |
Biogen sees ‘encouraging’ trends for postpartum depression drug
|
Apr 24 |
Biogen to invest more in launch of Alzheimer’s drug Leqembi
|
Apr 24 |
Biogen says uptake for Alzheimer’s therapy is improving
|
Apr 24 |
Biogen Non-GAAP EPS of $3.67 beats by $0.21, revenue of $2.29B misses by $30M
|
Apr 24 |
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
|
Apr 24 |
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
|
Apr 24 |
Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally
|